Phase III Evaluation of Once-Daily, Oral Therapy with ICL670 (Exjade®) Versus Deferoxamine in Patients with β-Thalassemia and Transfusional Hemosiderosis.
暂无分享，去创建一个
S. Perrotta | M. Cappellini | M. Bejaoui | G. Janka-Schaub | P. Giardina | D. Alberti | A. Kattamis | L. Ağaoğlu | Herbert Opitz | C. Ressayre-Djaffer